1700001E04Rik Inhibitors
Chemical inhibitors of 1700001E04Rik operate through diverse mechanisms to impede the function of this protein by interfering with its phosphorylation status or the signaling pathways it is involved in. Staurosporine, a broad-spectrum kinase inhibitor, can inhibit 1700001E04Rik by blocking its phosphorylation, which is a common mechanism of action for the regulation of protein activity. Similarly, LY294002 and Wortmannin can inhibit 1700001E04Rik if it is part of the PI3K/Akt pathway by obstructing the PI3K-dependent phosphorylation steps necessary for its activity. Inhibition of PI3K by these chemicals leads to a decrease in Akt signaling, which may be crucial for 1700001E04Rik function. Rapamycin, which targets mTORC1, can inhibit 1700001E04Rik if it is regulated by mTOR-dependent pathways by halting the downstream signaling processes required for 1700001E04Rik activity.
Moreover, PD98059 and U0126, both MEK inhibitors, can inhibit the ERK pathway, potentially reducing the phosphorylation and subsequent activation of 1700001E04Rik if it lies downstream of this pathway. SB203580, which selectively inhibits p38 MAP kinase, can also inhibit 1700001E04Rik by preventing its activation through phosphorylation if it is part of the p38 MAPK signaling pathway. SP600125, a JNK inhibitor, can reduce the activity of 1700001E04Rik by blocking the stress signaling pathways in which JNK is involved and which may regulate 1700001E04Rik. PP2, inhibiting Src family tyrosine kinases, can lead to reduced phosphorylation and activity of 1700001E04Rik if it is regulated by Src kinases. Lastly, Erlotinib and Gefitinib, both EGFR inhibitors, can impede the function of 1700001E04Rik by inhibiting the EGFR signaling pathway, which may be necessary for the phosphorylation and function of 1700001E04Rik. Triciribine, by inhibiting Akt, would also decrease 1700001E04Rik activity if its function is dependent on Akt-mediated signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. If 1700001E04Rik is a kinase or is regulated by kinase activity, staurosporine can inhibit this protein by preventing its phosphorylation, which is crucial for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 selectively inhibits PI3K, which is involved in the Akt signaling pathway. Since PI3K is upstream of many proteins, inhibition by LY294002 could lead to decreased phosphorylation of 1700001E04Rik if it is part of the Akt pathway, thereby inhibiting its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTORC1, which is a key regulator of protein synthesis and cell growth. The inhibition of mTORC1 could lead to functional inhibition of 1700001E04Rik if it is regulated by mTOR-dependent pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the activation of MAPK/ERK. If 1700001E04Rik acts downstream of the MAPK/ERK pathway, its inhibition could result in the functional inhibition of 1700001E04Rik by preventing its activation through phosphorylation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor similarly to PD98059, it could inhibit the function of 1700001E04Rik if the protein is a part of the MAPK/ERK signaling pathway by preventing its activation through phosphorylation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. Inhibition of p38 could result in functional inhibition of 1700001E04Rik if the protein is a part of the p38 MAPK signaling pathway, by impeding its phosphorylation and activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a covalent inhibitor of PI3K like LY294002, and if 1700001E04Rik is within the PI3K/Akt pathway, wortmannin inhibits its function by blocking the PI3K-dependent phosphorylation steps required for 1700001E04Rik activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is involved in stress signaling pathways. If 1700001E04Rik is regulated by JNK activity, inhibition by SP600125 could lead to a decrease in its phosphorylation and subsequent functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases, which regulate various signaling pathways. If 1700001E04Rik is a substrate or is regulated by Src kinases, inhibition by PP2 could lead to a decrease in phosphorylation of 1700001E04Rik, inhibiting its function. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. If 1700001E04Rik is involved in signaling pathways downstream of EGFR, erlotinib can lead to its functional inhibition by blocking the downstream signaling required for 1700001E04Rik activity. | ||||||